» Articles » PMID: 31570931

Biochemical Verification of Tobacco Use and Abstinence: 2019 Update

Overview
Specialty Public Health
Date 2019 Oct 2
PMID 31570931
Citations 271
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The changing prevalence and patterns of tobacco use, the advent of novel nicotine delivery devices, and the development of new biomarkers prompted an update of the 2002 Society for Research on Nicotine and Tobacco (SRNT) report on whether and how to apply biomarker verification for tobacco use and abstinence.

Methods: The SRNT Treatment Research Network convened a group of investigators with expertise in tobacco biomarkers to update the recommendations of the 2002 SNRT Biochemical Verification Report.

Results: Biochemical verification of tobacco use and abstinence increases scientific rigor and is recommended in clinical trials of smoking cessation, when feasible. Sources, appropriate biospecimens, cutpoints, time of detection windows and analytic methods for carbon monoxide, cotinine (including over the counter tests), total nicotine equivalents, minor tobacco alkaloids, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol are reviewed, as well as biochemical approaches to distinguishing cigarette smoking from use of electronic nicotine delivery devices (ENDS).

Conclusions: Recommendations are provided for whether and how to use biochemical verification of tobacco use and abstinence. Guidelines are provided on which biomarkers to use, which biospecimens to use, optimal cutpoints, time windows to detection, and methodology for biochemical verifications. Use of combinations of biomarkers is recommended for assessment of ENDS use.

Implications: Biochemical verification increases scientific rigor, but there are drawbacks that need to be assessed to determine whether the benefits of biochemical verification outweigh the costs, including the cost of the assays, the feasibility of sample collection, the ability to draw clear conclusions based on the duration of abstinence, and the variability of the assay within the study population. This paper provides updated recommendations from the 2002 SRNT report on whether and how to use biochemical markers in determining tobacco use and abstinence.

Citing Articles

Intensive smoking cessation treatment as an adjunct to concurrent psychotherapy: study protocol for a randomized controlled trial.

Sunkel E, Machulska A, Neubert M, Klucken T Trials. 2025; 26(1):76.

PMID: 40033439 PMC: 11874795. DOI: 10.1186/s13063-025-08781-2.


Perioperative Intensive Smoking Cessation Intervention Among Smokers Who Underwent Transurethral Resection of Bladder Tumor (TURBT) in Two Different Settings: A Randomized Controlled Trial.

Lydom L, Lauridsen S, Liljendahl M, Schmedes A, Joensen U, Tonnesen H Cancers (Basel). 2025; 17(4).

PMID: 40002306 PMC: 11853449. DOI: 10.3390/cancers17040713.


Unveiling the Complexities of Medications, Substance Abuse, and Plants for Recreational and Narcotic Purposes: An In-Depth Analysis.

Predescu I, Jijie A, Patrascu D, Pasc A, Piros E, Trandafirescu C Pharmacy (Basel). 2025; 13(1).

PMID: 39998006 PMC: 11859396. DOI: 10.3390/pharmacy13010007.


Identifying Patterns of Tobacco Use and Associated Cardiovascular Disease Risk Through Machine Learning Analysis of Urine Biomarkers.

Siegel N, Zhao J, Benjamin E, Bhatnagar A, Hall J, Stokes A JACC Adv. 2025; 4(3):101630.

PMID: 39985885 PMC: 11904550. DOI: 10.1016/j.jacadv.2025.101630.


Adherence to a digital therapeutic mediates the relationship between momentary self-regulation and health risk behaviors.

Plaitano E, McNeish D, Bartels S, Bell K, Dallery J, Grabinski M Front Digit Health. 2025; 7:1467772.

PMID: 39981105 PMC: 11841403. DOI: 10.3389/fdgth.2025.1467772.


References
1.
Pirkle J, Bernert J, Caudill S, Sosnoff C, Pechacek T . Trends in the exposure of nonsmokers in the U.S. population to secondhand smoke: 1988-2002. Environ Health Perspect. 2006; 114(6):853-8. PMC: 1480505. DOI: 10.1289/ehp.8850. View

2.
Achilihu H, Feng J, Wang L, Bernert J . Tobacco Use Classification by Inexpensive Urinary Cotinine Immunoassay Test Strips. J Anal Toxicol. 2018; 43(2):149-153. PMC: 7014560. DOI: 10.1093/jat/bky075. View

3.
Anderson K, Carmella S, Ye M, Bliss R, Le C, Murphy L . Metabolites of a tobacco-specific lung carcinogen in nonsmoking women exposed to environmental tobacco smoke. J Natl Cancer Inst. 2001; 93(5):378-81. DOI: 10.1093/jnci/93.5.378. View

4.
Roethig H, Munjal S, Feng S, Liang Q, Sarkar M, Walk R . Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers. Nicotine Tob Res. 2009; 11(10):1216-25. DOI: 10.1093/ntr/ntp126. View

5.
Simoni M, Baldacci S, Puntoni R, Pistelli F, Farchi S, Lo Presti E . Plasma, salivary and urinary cotinine in non-smoker Italian women exposed and unexposed to environmental tobacco smoking (SEASD study). Clin Chem Lab Med. 2006; 44(5):632-8. DOI: 10.1515/CCLM.2006.098. View